Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

A phase 3 trial used serial ctDNA testing for up to a year after cystectomy for muscle-invasive bladder cancer to select who received adjuvant atezolizumab. The abstract does not name the assay.

The New England Journal of MedicinePubMed 41124204DOI 10.1056/NEJMoa2511885